Ironwood Pharmaceuticals
IRWD
251 hedge funds and large institutions have $1.91B invested in Ironwood Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 87 increasing their positions, 94 reducing their positions, and 26 closing their positions.
113% more call options, than puts
Call options by funds: $24.5M | Put options by funds: $11.5M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
22% more capital invested
Capital invested by funds: $1.56B → $1.91B (+$349M)
4.72% more ownership
Funds ownership: 102.33% → 107.05% (+4.7%)
1% more funds holding
Funds holding: 248 → 251 (+3)
7% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$23.7M |
| 2 |
AC
Armistice Capital
New York
|
+$22.2M |
| 3 |
Man Group
London,
United Kingdom
|
+$14.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$24.1M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$13M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.4M |
| 4 |
Two Sigma Investments
New York
|
-$8M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$4.98M |
IRWD Hedge Fund Activity: Q4 2023 in Review
251 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2023, worth a combined $1.91B — up 22% from $1.56B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new IRWD positions and 26 closed out — a net gain of 6 holders — while 87 added to existing stakes and 94 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $23.7M. The largest seller was Dimensional Fund Advisors, cutting an estimated $24.1M.
- 251 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2023, up from 248 in Q3 2023.
- Funds reported $1.91B of Ironwood Pharmaceuticals stock for Q4 2023, up 22% quarter-over-quarter.
- 32 funds opened new Ironwood Pharmaceuticals positions in Q4 2023 and 26 closed out, a net change of +6 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $23.7M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2023 was Dimensional Fund Advisors, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2023.